Prognostic significance of preoperative systemic inflammatory biomarkers in patients with hepatocellular carcinoma after microwave ablation and establishment of a nomogram

Shuai Wang1,2,3, Yan Deng2,3, Xiao Yu2, Xue-Wen Zhang2, Cheng-Long Huo2, Zhen-Gang Sun2,3,* & Hong Chang1,*

The study aimed to evaluate the prognostic significance of preoperative systemic inflammatory biomarkers including albumin to globulin ratio (AGR), neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), and platelet to lymphocyte ratio (PLR) and establish a nomogram in hepatocellular carcinoma (HCC) patients after microwave ablation (MWA). 192 HCC patients receiving MWA as initial therapy from the first ward of hepatobiliary surgery were classified as training cohort. Whereas, 84 patients from the second of hepatobiliary surgery were classified as validation cohort. Kaplan–Meier (KM) method and univariate analyses showed that AGR, NLR, LMR, and PLR were significantly associated with OS in the training cohort. Multivariate analysis including clinicopathologic features screened out independent predictors including ascites, tumor size, cancer embolus, AGR, and PLR. Based on those variables, a nomogram for predicting OS was established. The C-index was 0.794 in the training cohort and 0.772 in the validation cohort. Calibration plots identified the nomogram performed well with an ideal model. Compared with Barcelona Clinic Liver Cancer (BCLC) staging system and simple tumor size, the nomogram showed better predictive ability. Besides, the nomogram discovered the highest diagnostic accuracy in predicting postoperative clinical outcome than the combination of the present models with tumor size. In conclusion, the constructed nomogram could accurately predict individualized survival probability and might support clinician in individual treatment optimization and clinical decision-making.

Hepatocellular carcinoma (HCC) ranks sixth most lethal malignancies globally, which attracts significant attention due to its aggressive biologic behavior and poor clinical prognosis 1,2. Now radical resection, liver transplantation and microwave ablation (MWA) are the main curative treatments3,4. Due to multifocal node or poor liver function resulting from severe cirrhosis, many patients have missed the chance of complete resection5. Liver transplantation may be another option for those patients, but the surgery is often unfeasible because of the shortage of donors6. Therefore, ablation may be a unique radical treatment for those patients, though HCC patients after ablation has been reported at higher 5-year recurrence rate and equal 5-year overall survival (OS) time compared to those after radical resection or liver transplantation7,8.

1Department of Hepatobiliary Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, No. 9677, Jingshi Road, Lixia District, Jinan 500212, Shandong, China. 2Department of Hepatobiliary Surgery, Jing Zhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jing Zhou 434020, Hubei, China. 3These authors contributed equally: Shuai Wang and Yan Deng. *email: 669210966@qq.com; drchanghong@126.com
Despite an improving progress in the multimodal therapy, the survival benefit remain to be limited\(^9\). Hence, there is a need to discover appropriate markers for evaluating prognosis to achieve precise individualized therapy in HCC patients. Nomogram established based on multiple independent risk factors is a statistical model with a high reliability.

Recently, it's suggested that systemic inflammatory response functions as a vital role in initiation, progression, metastasis, and treatment resistance of malignancy tumor and then it might correlate with worse prognosis\(^10,11\). What is more, systemic inflammatory response of malignancy patients could be presented by the changing of peripheral blood cell counts, including neutrophil, lymphocyte, monocyte, platelet, globulin and so on\(^12\). Based on those cell counts, inflammatory response markers including albumin to globulin ratio (AGR), neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), and platelet to lymphocyte ratio (PLR) have been proven to be independently prognostic factors in various malignancy\(^13–15\). Published studies have revealed that NLR, LMR, and PLR might be correlated with outcome in HCC patients after microwave ablation\(^16–18\). To the best of our knowledge, few studies evaluated the associations of all the inflammatory markers including AGR with prognosis and no more relevant nomogram was established among HCC patients after MW A.

Hence, the present aimed to evaluate the prognostic significance of preoperative AGR, NLR, LMR and PLR and establish a prognostic nomogram to predict OS in HCC patients after MW A.

### Results

**Clinicopathological characteristics.** Baseline clinicopathological characteristics of 276 patients (194 in the training group and 84 in the validation group) were summarized in Table 1. All the clinicopathological variables excepting cancer embolus were matched between two cohorts \(P > 0.050\). Compared with the validation group, the presence of cancer embolus in the training cohort was significantly less. The median follow-up time was 37.5 months (range: 6.0–77.0 months) for the training group and 38.5 (range: 6.0–79.0 months) for the validation group. Median time of OS was 18 months (range 6–79 months). As showed in Fig. 1, the 1-, 3-, and 5-year OS rates were 85.50%, 58.40%, and 39.30% for the training cohort, 84.30%, 54.30% and 44.30% for the validation cohort, respectively. KM curves showed there was no significant difference in overall survival time between two cohorts \(P > 0.050\).

**Time ROC curve analysis in training cohort.** Time ROC curve analysis to explore the predictive value of systemic inflammatory biomarkers. As shown in Fig. 2, PLR, AGR, NLR, and LMR showed the well predictive ability in predicting 1- (AUC: 0.610 for AGR, 0.734 for NLR, and 0.630 for LMR, 0.700 for PLR), 3- (AUC: 0.671

| Variable                           | Training cohort (n = 192) n/median (range) | Validation cohort (n = 84) n/median (range) | \(P\) value |
|------------------------------------|-------------------------------------------|-------------------------------------------|------------|
| Age (years)                        | 55 (29–83)                                | 53.5 (27–81)                              | 0.209      |
| Gender (male/female)               | 145/49                                    | 64/20                                     | 0.797      |
| Hypertension (present/absent)      | 33/159                                    | 14/70                                     | 0.916      |
| Diabetes (present/absent)          | 21/171                                    | 10/74                                     | 0.815      |
| Smoking (present/absent)           | 53/139                                    | 24/60                                     | 0.869      |
| Drinking (present/absent)          | 40/152                                    | 23/61                                     | 0.233      |
| Liver cirrhosis (present/absent)   | 123/69                                    | 53/31                                     | 0.878      |
| Ascites (present/absent)           | 19/171                                    | 9/75                                      | 0.836      |
| HBV infection (present/absent)     | 143/49                                    | 61/23                                     | 0.746      |
| HCV infection (present/absent)     | 23/169                                    | 12/72                                     | 0.596      |
| AFP (ng/ml)                        | 32.30 (1.15–105,184.00)                   | 26.83 (1.25–20,320.00)                    | 0.359      |
| Child–Pugh (A/B)                   | 166/26                                    | 68/16                                     | 0.241      |
| Tumor size (<3/≥3) (cm)            | 158/34                                    | 70/24                                     | 0.122      |
| Tumor number (1/>1)                | 146/46                                    | 56/28                                     | 0.106      |
| BCLC stage (A/B/C/D)               | 24/120/23/25                              | 6/45/17/16                                | 0.90       |
| Cancer embolus (present/absent)    | 10/182                                    | 16/68                                     | <0.001     |
| Tumor capsule (intact/incomplete)  | 136/56                                    | 56/28                                     | 0.234      |
| Serum albumin (g/L)                | 36.95 (21.79–49.30)                       | 36.525 (25.40–49.54)                     | 0.685      |
| Globulin (g/L)                     | 29.23 (8.80–52.02)                        | 28.90 (16.91–41.20)                      | 0.144      |
| Lymphocyte (k/mm\(^3\))           | 1.08 (0.08–3.48)                          | 1.22 (0.34–3.27)                         | 0.184      |
| Monocyte (k/mm\(^3\))             | 0.32 (0.01–3.13)                          | 0.36 (0.02–1.39)                         | 0.915      |
| Platelet (k/mm\(^3\))             | 100.00 (34.00–408.00)                     | 113.00 (49.00–207.00)                     | 0.128      |
| Neutrophil (k/mm\(^3\))           | 2.32 (0.52–17.70)                         | 2.44 (0.80–16.30)                        | 0.446      |

Table 1. Baseline demographics and clinical characteristics of patients in training cohort and validation cohort. \(P\) value of less than 0.050 was considered to indicate significant difference. AFP alpha-fetoprotein, HBV hepatitis B virus, HCV hepatitis C virus, BCLC Barcelona clinic liver cancer.
Associations of biomarkers with clinicopathological features in training cohort. Detail associations of AGR, NLR, LMR, and PLR with baseline clinicopathological factors were assessed in Table 2. Obviously, AGR was correlated to liver cirrhosis and ascites. Tumor size was significantly associated with NLR, PLR, and LMR, whereas high PLR and low LMR were prone to appear in patients with cancer embolus.

Independent risk factors in the training cohort. Based on the median value of systemic inflammatory biomarkers, all the patients were classified into high- and low- risk groups, respectively. As shown in Fig. 3, KM curves confirmed that AGR, NLR, PLR, and LMR were strong predictors of OS. Results from univariate analysis showed that BCLC staging system, ascites, tumor size, cancer embolus. AGR, NLR, LMR, and PLR were significantly indicators. In multivariate analysis, ascites (HR: 2.194; 95% CI: 1.135–4.238; \( P = 0.019 \)), tumor size (HR: 2.201; 95% CI: 1.226–3.950; \( P = 0.008 \)), cancer embolus (HR: 2.372; 95% CI: 1.327–4.238; \( P = 0.004 \)), AGR

Figure 1. Kaplan–Meier estimate of the postoperative overall survival (OS) of patients with HCC stratified by different cohorts. The figure was performed using R software (version 3.3.1, https://www.r-project.org/).

Figure 2. Comparison of the predictive ability of systemic inflammatory biomarkers in predicting 1- (A), 3- (B), and 5-year (C) survival. The figure was performed using R software (version 3.3.1, Vienna, Austria, https://www.r-project.org/).
| Variables          | AGR Median(range) | AGR P value | NLR Median(range) | NLR P value | LMR Median(range) | LMR P value | PLR Median(range) | PLR P value |
|-------------------|-------------------|-------------|-------------------|-------------|-------------------|-------------|-------------------|-------------|
| Total             | 1.252 (0.517–4.945) | 1.907 (0.321–19.833) | 3.484 (0.026–168.000) | 0.335       | 0.945             | 0.867       | 0.997             |
| Age(years) < 60   | 1.324 (0.619–4.945) | 1.907 (0.321–19.833) | 3.455 (0.620–168.000) |            |                   |             | 85.965 (16.667–413.115) |
| ≥ 60              | 1.188 (0.517–2.086) | 1.907 (0.615–16.729) | 3.566 (0.256–27.500) | 0.766       | 0.317             | 0.361       | 88.763 (27.211–962.500) |
| Gender Male       | 1.257 (0.517–4.943) | 1.952 (0.321–16.729) | 3.451 (0.620–168.000) | 0.010       | 0.557             | 0.679       | 86.632 (16.667–413.115) |
| Diabetes melitus  | 1.244 (0.668–2.114) | 1.874 (0.500–19.833) | 3.682 (0.026–66.5000) | 0.109       | 0.529             | 0.679       | 85.965 (32.727–962.500) |
| Hypertension      | 0.808             | 0.557       | 0.679             | 0.169       |                   |             |                   |
| Present           | 1.324 (0.517–4.943) | 1.935 (0.616–10.599) | 3.720 (0.262–27.500) | 0.107       |                   |             | 80.769 (33.921–962.500) |
| Absent            | 1.247 (0.619–3.732) | 1.890 (0.321–19.833) | 3.375 (0.620–168.000) | 0.035       |                   |             | 87.347 (16.667–413.115) |
| Smoking Present   | 1.156 (0.648–4.943) | 1.812 (0.616–6.758)  | 3.620 (1.719–7.111)  | 0.575       |                   |             | 72.137 (27.211–370.968) |
| Absent            | 1.252 (0.517–3.732) | 1.933 (0.321–19.833) | 3.374 (0.026–168.000) | 0.469       |                   |             | 89.604 (16.667–962.500) |
| Drinking Present  | 0.217             | 0.175       | 0.107             | 0.668       |                   |             |                   |
| Absent            | 1.247 (0.517–3.532) | 1.895 (0.321–19.833) | 3.447 (1.008–12.429) | 0.634       |                   |             | 85.531 (27.211–962.500) |
| Liver cirrhosis   | 0.010             | 0.172       | 0.545             | 0.101       |                   |             |                   |
| Present           | 1.193 (0.517–3.732) | 1.836 (0.321–9.985)  | 3.616 (0.620–66.500) | 0.954       |                   |             | 84.132 (32.727–962.500) |
| Absent            | 1.384 (0.687–4.943) | 2.132 (0.573–19.833) | 3.214 (0.026–168.000) | 0.004       |                   |             | 94.286 (32.727–962.500) |
| Ascites Present   | 0.004             | 0.224       | 0.072             | 0.263       |                   |             |                   |
| Absent            | 1.324 (0.517–4.973) | 1.903 (0.321–19.833) | 3.566 (0.026–168.000) | 0.227       |                   |             | 86.136 (16.667–962.500) |
| HBV infection     | 0.637             | 0.040       | 0.227             | 0.701       |                   |             |                   |
| Present           | 1.250 (0.517–3.532) | 1.849 (0.394–19.833) | 3.616 (0.620–168.000) | 0.409       |                   |             | 88.293 (16.667–413.115) |
| Absent            | 1.252 (0.626–4.943) | 2.152 (0.321–16.729) | 3.159 (0.026–7.111)  | 0.509       |                   |             | 81.481 (27.211–962.500) |
| HCV infection     | 0.049             | 0.828       | 0.701             | 0.073       |                   |             |                   |
| Present           | 1.041 (0.626–3.732) | 2.152 (0.321–8.750) | 3.455 (0.026–6.000)  | 0.243       |                   |             | 78.561 (27.211–962.500) |
| Absent            | 1.257 (0.517–4.945) | 1.881 (0.394–19.833) | 3.492 (0.620–168.000) | 0.267       |                   |             | 87.347 (16.667–413.115) |
| AFP ≥ 20 ng/ml    | 1.314 (0.626–1.966) | 1.935 (0.321–10.599) | 3.000 (0.620–168.000) | 0.848       |                   |             | 98.765 (16.667–413.115) |
| < 20 ng/ml        | 1.252 (0.517–4.943) | 1.882 (0.500–19.833) | 3.677 (0.026–66.500) | 0.005       |                   |             | 84.000 (27.211–962.500) |
| Child–Pugh A      | 0.214             | 0.098       | 0.005             | 0.606       |                   |             |                   |
| B                 | 1.104 (0.517–1.966) | 2.704 (0.594–19.833) | 2.461 (0.620–27.500) | 0.006       |                   |             | 90.030 (33.508–392.157) |
| Tumor size        | 0.783             | 0.003       |                   |             |                   |             |                   |
| Continued         |                   |             |                   |             |                   |             |                   |
(HR: 0.465; 95% CI: 0.218–0.991; P = 0.047), and PLR (HR: 1.003; 95% CI: 1.001–1.005; P = 0.014) were further screened out as independent risk factors for OS (Table 3).

Prognostic nomogram for survival. Based on those independent risk factors, a prognostic nomogram was constructed for OS prediction in the training cohort. Each subgroup variable was assigned a corresponding score for the establishment of the nomogram. The larger points in the nomogram indicated poorer OS. Each variable was assigned a weighted number of points in the nomogram, then the sum of points for each patient was in accordance with a specific 1-, 3-, and 5-year OS rates (Fig. 4A).

Validation of the constructed nomograms. For internal validation, boot-strapped calibration plots predicting 1-, 3-, and 5-year OS (Fig. 4B–D) performed well with ideal model. Besides, nomograms exhibited good efficacy in estimating postoperative OS with a high C-index of 0.794 in the training cohort. For external validation in the validation cohort, the C-index was 0.772, and the calibration plots showed good probability consistencies between the nomogram prediction and actual observation (Fig. 4E–G).

Discriminatory powers of the nomogram. Each patient would get a score for risk stratification of death based on the established nomogram. Patients were further divided into high- and low- risk groups based on the median value of riskscore. KM curves and log-rank tests were performed to compare the survival of different groups in the training and validation cohorts. Results showed the constructed nomogram showed clearly different prognostic strata in the training (Fig. 5A) and validation cohorts (Fig. 5B), with both the log-rank P values being less than 0.001.

Comparison of predictive accuracy between nomogram, BCLC staging system and tumor size in samples’ cohort. The discrimination ability of the nomogram with BCLC staging system and tumor size were compared in OS prediction. Results from time-dependent ROC curve analyses showed the nomogram displayed better accuracy in predicting OS than BCLC staging system and simple tumor size. The time-dependent AUC of the nomogram for predicting 1-, 3-, and 5-year OS was 0.725, 0.733, and 0.691, respectively. The time-dependent AUCs of the nomogram for predicting 1-, 3-, and 5-year OS were significantly larger than BCLC staging system and simple tumor size (Fig. 6A–C).

Comparison of predictive power between the nomogram and present models. Subsequently, the predictive power of the constructed nomogram with present models including PNI, King score, GUCI, FIB4, APRI, S-index, and GPR was compared based on C-index. As shown in Table 4, the nomogram discovered the highest diagnostic accuracy in predicting postoperative clinical outcome than BCLC staging system as well as the combination of the present models with tumor size.

| Variables         | AGR Median (range) | NLR Median (range) | LMR Median (range) | PLR Median (range) |
|-------------------|--------------------|--------------------|--------------------|--------------------|
| <3 cm             | 1.287 (0.517–4.945)| 1.871 (0.321–19.833)| 3.712 (0.026–168.000)| 83.766 (26.693–962.500) |
| ≥3 cm             | 1.218 (0.668–2.086)| 3.125 (0.853–10.599)| 2.408 (0.989–27.500)| 118.256 (16.667–413.115) |
| Tumor number      |                    |                    |                    |                    |
| 1                 | 1.242 (0.517–4.943)| 1.920 (0.321–19.833)| 3.407 (0.026–66.500)| 86.956 (26.693–962.500) |
| >1                | 1.403 (0.758–3.732)| 1.891 (0.853–10.599)| 4.121 (0.989–168.000)| 83.595 (16.667–253.763) |
| Cancer embolus    | 0.224              | 0.053              | 0.030              | 0.004              |
| Present           | 1.164 (0.575–1.685)| 3.221 (0.954–9.985)| 2.185 (0.989–4.929)| 118.256 (61.481–413.115) |
| Absent            | 1.287 (0.517–4.943)| 1.877 (0.321–19.833)| 3.611 (0.026–168.000)| 84.000 (16.667–962.500) |
| Tumor capsule     | 0.565              | 0.994              | 0.606              | 0.924              |
| Intact            | 1.277 (0.517–4.943)| 1.920 (0.394–19.833)| 3.407 (0.620–168.000)| 85.098 (16.667–392.157) |
| Incomplete        | 1.235 (0.626–3.732)| 1.866 (0.321–16.729)| 3.721 (0.026–66.500)| 89.545 (26.693–962.500) |

Table 2. Associations of inflammation-based markers with clinicopathologic characteristics in training cohort. P value of less than 0.050 was considered to indicate significant difference. The P value was calculated by nonparametric Wilcoxon rank-sum test. AFP alpha-fetoprotein, HBV hepatitis B virus, HCV hepatitis C virus, AGR albumin to globulin ratio, NLR neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, LMR lymphocyte to monocyte ratio.
Discussion

Despite an improving progress in the multimodal therapy, the survival benefit of HCC patients after surgery remains to be limited. The risk of postoperative HCC early death must be predicted and stratified to allow early intervention for high-risk patients. However, the internationally recognized and widely used systems include the AJCC TNM and BCLC staging systems have not achieved satisfactory results in predicting the prognosis, mainly because these systems simple focus on the tumor clinical characteristics like morphological traits\textsuperscript{19}. Clearly, malignant patients’ clinical outcome is determined not solely by tumor characteristics that only reflect the degree of cancer progression, but also by host-related factors such as host response to systemic inflammation\textsuperscript{20}. Hence, we expected that a combination of host-related factors with conventional tumor characteristics could accurately predict individualized OS probability in HCC patients after WMA.

Recently, the importance of host inflammatory microenvironment in carcinogenesis, tumor growth, invasion, and metastasis has been recognized\textsuperscript{11,21,22}. Better understanding the associations of host systemic inflammation with cancer might contribute to disease prevention and treatment\textsuperscript{23}. Host systemic inflammation response could well reflect by changing in circulating white blood cell counts\textsuperscript{12}. However, single blood cell count easily be affected by host swollen or dehydrated\textsuperscript{24}. Thus, it alone might be difficult to reflect the association of host systemic inflammation with patients’ outcome. Hence, systemic inflammatory indexes including AGR, NLR, LMR, and PLR computed by combination of those cell counts or protein levels have been considered as prognostic indicators in predicting the clinical outcome of patients with malignant tumors.

In the present study, we investigated the prognostic significance of pretreatment AGR, NLR, LMR, and PLR in HCC patients undergoing MWA. Results showed that all the biomarkers were significantly associated with
that increasing infiltration of lymphocytes in circulating blood has been statically related to well prognosis. Nutrition condition, but also associates with host systematic inflammation. Hypoalbuminemia is a common finding in patients with malignancy. Inhibiting inflammatory pathways by regularly taking aspirin could also contribute to better overall survival (OS) and recurrence-free survival (RFS) for HCC patients.

Cancer cell could produce a large number of platelet-derived growth factors, which conduce to sustain proliferation and invasion. Platelet count is associated with tumor progression. Meta-analyses and studies have evaluated the associations of platelet count with malignant tumor.

Finally, meta-analyses and studies have evaluated the associations of platelet count with malignant tumor. Cancer cell could produce a large number of platelet-derived growth factors, which conduce to sustain proliferation and invasion. Platelet count is associated with tumor progression. Meta-analyses and studies have evaluated the associations of platelet count with malignant tumor.

Table 3. Univariate and multivariate Cox proportional hazards regression analyses of overall survival in the training cohort. *P* value of less than 0.050 was considered to indicate significant difference. AGR albumin to globulin ratio, NLR neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, LMR lymphocyte to monocyte ratio, HR hazard ratio, CI confidence interval.

| Variables          | Factor                             | Univariate analysis | Multivariate analysis |
|--------------------|------------------------------------|---------------------|-----------------------|
|                    |                                    | HR (95% CI)         | P value               | HR (95% CI)         | P value               |
| Age                | ≥ 60 vs < 60 (years)               | 1.408 (0.838–2.366) | 0.196                 | 1.649 (1.067–2.537) | 0.014                 |
| Gender             | Male vs female                     | 1.155 (0.660–2.023) | 0.614                 | 1.247 (0.703–2.211) | 0.450                 |
| Hypertension       | Present vs absent                  | 0.945 (0.480–1.862) | 0.870                 | 1.247 (0.703–2.211) | 0.450                 |
| Diabetes           | Present vs absent                  | 0.340 (0.106–1.086) | 0.069                 | 1.247 (0.703–2.211) | 0.450                 |
| Smoking            | Present vs absent                  | 0.932 (0.520–1.669) | 0.812                 | 1.247 (0.703–2.211) | 0.450                 |
| Drinking           | Present vs absent                  | 1.035 (0.548–1.955) | 0.915                 | 1.247 (0.703–2.211) | 0.450                 |
| Liver cirrhosis    | Present vs absent                  | 1.188 (0.699–2.020) | 0.525                 | 1.247 (0.703–2.211) | 0.450                 |
| Ascites            | Present vs absent                  | 1.946 (1.036–3.654) | **0.038**             | 2.194 (1.135–4.238) | **0.019**             |
| HBV infection      | Present vs absent                  | 1.247 (0.703–2.211) | 0.450                 | 1.247 (0.703–2.211) | 0.450                 |
| HCV infection      | Present vs absent                  | 0.632 (0.253–1.580) | 0.326                 | 1.247 (0.703–2.211) | 0.450                 |
| AFP                | ≥ 20 vs < 20 (ng/ml)               | 1.441 (0.857–2.424) | 0.169                 | 1.247 (0.703–2.211) | 0.450                 |
| Child–Pugh         | A vs B                             | 1.152 (0.592–2.218) | 0.672                 | 1.247 (0.703–2.211) | 0.450                 |
| Tumor size         | ≥ 3 cm vs <3 cm                    | 3.936 (2.380–6.509) | **< 0.001**           | 2.201 (1.226–3.950) | **0.008**             |
| Tumor number       | > 1 vs 1                           | 1.709 (0.835–3.496) | 0.142                 | 1.709 (0.835–3.496) | 0.142                 |
| Cancer embolus     | Present vs absent                  | 3.891 (2.394–6.323) | **< 0.001**           | 2.372 (1.327–4.238) | **0.004**             |
| Tumor capsule      | Intact vs incomplete               | 1.275 (0.729–2.229) | 0.395                 | 1.275 (0.729–2.229) | 0.395                 |
| BCLC stage         | Per 1 stage increasing             | 1.785 (1.389–2.295) | **< 0.001**           | NA                   | NA                    |
| AGR                | Per 1 increasing                   | 0.296 (0.139–0.632) | **0.002**             | 0.465 (0.218–0.991) | **0.047**             |
| NLR                | Per 1 increasing                   | 1.130 (1.061–1.205) | **< 0.001**           | 1.080 (0.990–1.179) | 0.082                 |
| LMR                | Per 1 increasing                   | 0.949 (0.849–1.061) | 0.356                 | 0.949 (0.849–1.061) | 0.356                 |
| PLR                | Per 1 increasing                   | 1.004 (1.002–1.006) | **< 0.001**           | 1.003 (1.001–1.005) | **0.014**             |

OS. Multivariate analysis further verified that preoperative AGR and PLR were the independent risk biomarker in predicting postoperative OS. In the course of the investigation, we also found biomarkers were significantly associated with advanced tumor and poor host nutrition, which also provided sturdy proof that the progress of the tumor cannot stand away from poor host nutrition and systemic inflammation syndrome.

Although prognostic significance of inflammatory biomarkers has been verified, the underlying mechanism largely remains not be understood. Several following reasons might partly explain the mechanism. Firstly, albumin coming from the liver mainly maintains osmotic pressure and functions as a vector to transport various host metabolic substances. Besides, albumin as an antioxidant has ability to buffer biochemical substance of host internal environment, stabilize cell growth and DNA replication. Albumin not only significantly reflects host nutrition condition, but also associates with host systematically chronic inflammation. Hypoalbuminemia could weaken host defense system, thus increasing susceptibility to infection and cytokine. Secondly, globulin consisted of all the proinflammatory protein could largely explain host systematic inflammatory response. Inflammation can alter tumor cell biological characteristic and destroy immune function, thus leading to malignancy patients’ poor clinical outcome. HBV infection is associated with HCC occurring and relapsing via mediating HBV immunogenic protein expression, thus resulting in a powerful chronic inflammation. Besides, the present study also showed that patients with HBV infection had significantly worse RFS compared with counterparts. Inhibiting inflammatory pathways by regularly taking aspirin could also contribute to better OS and RFS for malignancy patients. Finally, meta-analyses and studies have evaluated the associations of platelet count with malignant tumor. Cancer cell could produce a large number of platelet-derived growth factors, which conduce to sustain proliferative signal and promote tumor progression.

Recently, nomograms have shown high reliability for predicting tumor progression as a statistical model. Subsequently, we construct a prognostic nomogram for OS in HCC patients after MWA based on those powerful biomarkers and conventional clinicopathological markers including ascites, tumor size, and cancer embolus. Calibration plots identified that nomogram performed well in predicted 1-, 3-, and 5-year OS with ideal model in the training and validation cohorts, which indicated that the nomogram was well calibrated to predict OS in HCC patients after MWA at assessing the performance characteristics. Besides, the nomogram exhibited good efficacy in estimating postoperative OS with a high C-index in the training and validation cohorts. We divided the patients into low-, intermediate-, and high risk groups based on the total score of the nomogram in the
training and validation cohorts. Results showed the constructed nomogram showed clearly different prognostic strata in the training and validation cohorts, which confirmed the discriminatory accuracy of the constructed nomogram. According to the nomogram, we can assess the risk of early death of HCC after surgery and conduct early individualized interventions including early postoperative trans arterial chemoembolization (TACE) or postoperative immunoregulatory therapy for high-risk patients. The comparisons of predictive power between our nomograms and the conventional BCLC staging system as well as simple tumor size showed that the
Figure 5. Kaplan–Meier curves of different risk groups stratified by the median value of risk score calculated by the nomogram in the training (A) and validation (B) cohorts. The figure was performed using R software (version 3.3.1, Vienna, Austria, https://www.r-project.org/).

Figure 6. Time-dependent ROC curves for the OS in all samples’ cohort using the constructed nomogram, Barcelona Clinic Liver Cancer (BCLC) staging system and simple tumor size. The area under the curve (AUC) generated from their time-dependent ROC curves for predicting the OS at 1- (A), 3- (B), and 5-year (C) was presented. The figure was performed using R software (version 3.3.1, Vienna, Austria, https://www.r-project.org/).

Table 4. Ranking of discriminatory ability of the prognostic systems on the basis of C-index. C-index reflects the ability to predict survival: the greater the C-index, the more accurate the prognostic prediction. C-index concordance index, PNI prognostic nutritional index, BCLC Barcelona clinical liver cancer, GUCI Göteborg University Cirrhosis Index, FIB4 fibrosis-4 index, APRI aspartate-to-platelet ratio index, GPR gamma-glutamyl transpeptidase-to-platelet ratio, SD standard deviation.
constructed nomogram is infinitely superior. Anyway, the nomogram established in the present study showed a robust and remarkably prognostic prediction ability.

The present study might be disturbed by possible limitations as a single center, retrospective, and relatively small-sized sample, which might have had a negative impact on the findings. The findings remain to be confirmed by multicenter prospective clinical studies. In addition, relevant mechanism of systematic inflammatory response to tumor progress was not investigated in the present study. Thus further basic researches need to be done to define the detailed mechanism. Despite the limitations, the nomogram for predicting survival of HCC patients after MWA showed great discrimination and calibration ability.

Conclusion
In conclusion, our findings highlighted the prognostic value of systemic inflammatory biomarkers and provide extra evidence for the treatment of HCC and understanding of the possible mechanism of systemic inflammatory reaction in the development and progression of HCC. Furthermore, we established and validated a robust nomogram that could accurately predict individualized survival probability and might support clinician in individual treatment optimization and clinical decision-making for HCC patients after MWA.

Materials and methods
Patients. A consecutive set of 327 HCC patients receiving MWA as initial therapy at Jing Zhou Central Hospital, the second clinical medical college, Yangtze University between December 2011 and September 2018 were included in the retrospective study. The following patients were excluded in the analysis: (1) patients with other types of malignancy (n = 2); (2) patients died of non-cancer reason (n = 3); (3) patients with autoimmune disease, systemic infection, or inflammation (n = 5); (4) patients with previous anti-inflammatory medications taken within 1-week (n = 3); (5) patients with severe disease including heart or renal failure (n = 3). (6) patients with incomplete data computed those inflammatory biomarkers (n = 15); (7) patients with incomplete follow-up data (n = 20). Eligible patients met the following criteria: (1) patients with complete peripheral blood cell counts data and follow-up data; (2) patients older than 18-year-old; (3) patients with newly diagnosed by the histological and/or radiology recommended by the America Association for the Study of the Liver Diseases guidelines. Finally, 276 patients remained and were analyzed in this study. Hepatobiliary surgery in our hospital were divided into two independent wards. Hence, 192 patients from the first ward of hepatobiliary surgery were classified as training cohort. Whereas, 84 patients from the second of hepatobiliary surgery were classified as validation cohort. All the HCC patients with HBV or HCV infection are routinely given oral antiviral drugs such as entecavir before surgery until their viral load was below the minimum, and they also regularly take antiviral drugs after surgery in our department. Approval of protocol was obtained from the Ethical Committee of Jing Zhou Central Hospital, the second clinical medical college, Yangtze University. Written informed consent was signed from every eligible patient and their family members. The methods were carried out based on the guidelines and regulations. Patients' records were anonymity and de-identified prior to analysis. The study was carried out in accordance with the Declaration of Helsinki.

MWA procedure. After routine preparation before the procedure, patients were performed by intravenous anesthesia. Laparoscopic exploration was used to confirm whether there were any other site metasteses. Then intraoperative ultrasound was first taken to confirm the puncture path, location, and the number of target lesion. MWA electrode probe was inserted along the path to reach the opposite edge of the tumor lesion through its center. After confirming the location of the MWA electrode probe, MWA treatment was performed. Microwave power was set to 55–70 W and the procedure lasted for 10–20 min. The distance from edge of the ablation zone center. After confirming the location of the MW A electrode probe, MW A treatment was performed. Microwave MW A electrode probe was inserted along the path to reach the opposite edge of the tumor lesion through its intraoperative ultrasound was first taken to confirm the puncture path, location, and the number of target lesion.

Follow-up. Routinely follow-up was conducted every 3 months for the first year, every 4 months for the second year, and every 6 months thereafter in our hospital. The detail content contains postoperative AFP, ultrasonic and/or abdominal computed tomography (CT). Follow-up was terminated in October 2019. When serum AFP value more than 20 ng/ml and ultrasonic/abdominal CT finds new focus, patient was considered to tumor recurrence. OS was defined as the interval between surgery and death or the last follow-up. Two clinicians completed follow-up and recorded, respectively.

Data collection. Baseline clinicopathological variables including age at surgery, gender, demographic data (hypertension, diabetes mellitus, smoking and drinking), tumor size, tumor number, Child-Pugh class, liver cirrhosis, hepatitis B virus (HBV), hepatitis C virus (HCV), ascites, caner embolus and capsule based radiological or ultrasonic results were obtained. Diabetes was defined as self-reported history of diabetes mellitus, diabetes medication uses or fasting glucose ≥ 126 mg/dl. Hypertension was defined based on a prior diagnosis of hypertension and/or current treatment with medications for hypertension. Whose patient used to smoke or drink and still did not stop at admission was supposed to be a smoker of drinker. Clinical, radiological criteria (computed tomography scan), and histological evidence were used to diagnose the presence of liver cirrhosis in all patients. patients with hepatitis B infection were defined as those who were seropositive for hepatitis B virus surface antigen, and patients with hepatitis C were defined as those who were seropositive for hepatitis C virus antibody in the study. Blood cell counts included neutrophil, lymphocyte, monocyte, platelet, and globulin were extracted from peripheral blood test prior to surgery.
As described previously, those systemic inflammatory markers are computed using the equations as follows: AGR = albumin/globulin, NLR = neutrophil/lymphocyte ratio, LMR = lymphocyte/monocyte, and PLR = platelet/lymphocyte.

**Statistical analysis.** The R package of “timeROC” was used to explore the predictive value of systemic inflammatory biomarkers. Based on the median value of systemic inflammatory biomarkers, all the patients were classified into high- and low-risk groups, respectively. (Kaplan–Meier) K-M survival curve was used to compare the prognosis of the high- and low-risk group patients. Whether normal distribution was studied was via Kolmogorov–Smirnov test. The relationships of those biomarkers with baseline clinicopathological variables were determined by the nonparametric Wilcoxon rank-sum test or the Kruskal Wallis test. All data were shown as median and range. Univariate Cox proportional hazards model was performed to assess significantly prognostic indicators. Variables showing significantly prognostic value in univariate Cox proportional hazards model were further analyzed in the final multivariate analysis. Based on those independent predictors, a prognostic nomogram was established by R Software version 3.3.1 using the package of rms in the training cohort. ROC curves, Harrell’s concordance indexes (C-index) and calibration plots were used to assess the performance characteristics of nomogram. C-index ranges from 0.5 (no predictive power) to 1 (perfect prediction). The results were externally validated using the validation cohort patients. C-indexes and calibration plots of both the training and validation cohort were based on 1000 bootstrap samples. Hence, each patient would get a score for risk stratification of death based on the established nomogram. Patients were further divided into high- and low-risk groups based on the median value of riskscore. KM curves and log-rank tests were performed to compare the survival of different groups in both cohorts.

Subsequently, the discrimination ability of our nomogram model, Barcelona Clinic Liver Cancer (BCLC) staging system and tumor size in predicting 1-, 3-, and 5-year survival was compared based on time-dependent ROC curves in all samples’ cohort. The corresponding time-dependent area under the curve (AUC) was also computed using the package of “timeROC”. Finally, the predictive performance of the nomogram was compared with the present model including the prognostic nutritional index (PNI)46, King score47, Göteborg University Cirrhosis Index (GUCCI)48, fibrosis-4 index (FIB4)49, Aspartate-to-platelet ratio index (APRI)50, S-index51, and gamma-glutamyl transpeptidase-to-platelet ratio (GPR)52. Statistical analyses were performed using SPSS software (version 23.0; IBM Corporation, Armonk, NY, USA) and R software (R Foundation for Statistical Computing, version 3.3.1, Vienna, Austria, http://www.r-project.org/) with packages including “survival”, “rms”, “foreign”, and “survivalROC” “timeROC” and “survminer”. Two-sided P-value < 0.05 was considered statistically significant in all the analyses of the study.

**Ethics declarations.** Approval of protocol was obtained from the Ethical Committee of Jing Zhou Central Hospital, the second clinical medical college, Yangtze University. Written informed consent was signed from every eligible patient and their family members. The methods were carried out based on the guidelines and regulations. Patients’ records were anonymity and de-identified prior to analysis. The study was carried out in accordance with the Declaration of Helsinki.

**Data availability**

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Received: 10 April 2021; Accepted: 21 June 2021
Published online: 05 July 2021

**References**

1. El-Serag, H. B. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology* **142**, 1264–1273 e1261. https://doi.org/10.1053/j.gastro.2011.12.061 (2012).
2. Shetty, S., Sharma, N. & Ghosh, K. Epidemiology of hepatocellular carcinoma (HCC) in hemophilia. *Crit. Rev. Oncol. Hematol.* **99**, 129–133. https://doi.org/10.1016/j.critrevonc.2015.12.009 (2016).
3. Reig, M., da Fonseca, L. G. & Faivre, S. New trials and results in systemic treatment of HCC. *J. Hepatol.* **68**, 525–533. https://doi.org/10.1016/j.jhep.2018.03.028 (2018).
4. de Lope, C. R., Tremosini, S., Forner, A., Reig, M. & Bruix, J. Management of HCC. *J. Hepatol.* **56**(Suppl 1), S75-87. https://doi.org/10.1053/j.jhepat.2018.03.028 (2018).
5. Chen, Z. B. et al. Microwave-assisted liver resection vs. clamp crushing liver resection in cirrhosis patients with hepatocellular carcinoma. *Int. J. Hyperthermia* **34**, 1359–1366. https://doi.org/10.1080/02656736.2018.1429678 (2018).
6. Chianchiano, P. et al. Distinction of intrahepatic metastasis from multicentric carcinogenesis in multifocal hepatocellular carcinoma using molecular alterations. *Hum. Pathol.* **72**, 127–134. https://doi.org/10.1016/j.humpath.2017.11.011 (2018).
7. Xia, Y. et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial. *JAMA Oncol.* https://doi.org/10.1001/jamaoncol.2019.4477 (2019).
8. Ni, J. Y. et al. Percutaneous ablation therapy versus surgical resection in the treatment for early-stage hepatocellular carcinoma: A meta-analysis of 21,494 patients. *J. Cancer Res. Clin. Oncol.* **139**, 2021–2033. https://doi.org/10.1007/s00432-013-1530-1 (2013).
9. Lin, S., Hoffmann, K. & Schemmer, P. Treatment of hepatocellular carcinoma: A systematic review. *Liver Cancer* **1**, 144–158. https://doi.org/10.1111/1758-4636.12828 (2012).
10. Lim, B., Woodward, W. A., Wang, X., Reuben, J. M. & Ueno, N. T. Inflammatory breast cancer biology: The tumour microenvironment is key. *Nat. Rev. Cancer* **18**, 485–499. https://doi.org/10.1038/s41568-018-0010-y (2018).
11. Amara, S. & Tiriveedhi, V. Inflammatory role of high salt level in tumor microenvironment (review). *Int. J. Oncol.* **50**, 1477–1481. https://doi.org/10.3892/ijo.2017.3936 (2017).
12. Diakos, C. I., Charles, K. A., McMillan, D. C. & Clarke, S. J. Cancer-related inflammation and treatment effectiveness. *Lancet Oncol.* **15**, e493–503. https://doi.org/10.1016/S1470-2045(14)70263-3 (2014).
13. Deng, Y. et al. Prognostic value of preoperative systemic inflammatory biomarkers in patients with gallbladder cancer and the establishment of a nomogram. Cancer Manag. Res. 11, 9025–9035. https://doi.org/10.2147/CMAR.D218119 (2019).

14. Zhang, Z. Y. et al. Prognostic value of preoperative hematological markers combined with molecular pathology in patients with diffuse gliomas. Aging (Albany NY) 11, 6252–6272. https://doi.org/10.18632/aging.102186 (2019).

15. Lv, G. Y., An, L., Sun, X. D., Hu, Y. L. & Sun, D. W. Pretreatment albumin to globulin ratio can serve as a prognostic marker in human cancers: A meta-analysis. Clin. Chim. Acta 476, 81–91. https://doi.org/10.1016/j.cca.2017.11.019 (2018).

16. Ni, Y. Y. et al. Comparison of albumin-bilirubin grade, platelet-Turcotte-Pugh classification for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation. Int. J. Hyperthermia 36, 841–853. https://doi.org/10.1080/02667362.2019.1646927 (2019).

17. Chu, M. O. et al. Pretreatment inflammation-based markers predict survival outcomes in patients with early stage hepatocellular carcinoma after radiofrequency ablation. Sci. Rep. 8, 16611. https://doi.org/10.1038/s41598-018-34543-z (2018).

18. Dan, J. et al. Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. PloS ONE 8, e58184. https://doi.org/10.1371/journal.pone.0058184 (2013).

19. Tellapuri, S., Sutphin, P. D., Beg, M. S., Singal, A. G. & Kalva, S. P. Staging systems of hepatocellular carcinoma: A review. Indian J. Gastroenterol. 37, 481–491. https://doi.org/10.1007/s12664-018-0915-0 (2018).

20. Ni, X. C. et al. Inflammation-nutrition score predicts prognosis of patients with resectable hepatocellular carcinoma. Int. J. Clin. Pract. 24, 825–835. https://doi.org/10.1111/ijcp.13042 (2019).

21. Eichizen, K., Oshima, H., Nakayama, M. & Oshima, M. The inflammatory microenvironment that promotes gastrointestinal cancer development and invasion. Adv. Biol. Regul. 68, 39–45. https://doi.org/10.1016/j.jbior.2018.02.001 (2018).

22. Garagnani, P., Pirazzini, C. & Franceschi, C. Colorectal cancer microenvironment: Among nutrition, gut microbiota, inflammation and epigenetics. Curr. Pharm. Des. 19, 765–778 (2013).

23. van Dijk, R. A. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfec-
tion. Int. J. Clin. Adv. Biol. Regul. Med. 4, 137–148. https://doi.org/10.14218/JCTH.2015.00012 (2015).

24. Fearon, K. C. et al. The immunobiology of cancer immunosurveillance and immunoediting. Oncoimmunology 4, e236729 (2015).

25. Wang, C. Q. et al. Sphingosine-1-phosphate promotes PDGF-dependent endothelial progenitor cell angiogenesis in human chon-
drosarcoma cells. Aging (Albany NY) 11, 11040–11053. https://doi.org/10.18632/aging.102508 (2019).

26. Wang, C. Q. et al. Sphingosine-1-phosphate promotes PDGF-dependent endothelial progenitor cell angiogenesis in human chondrosarcoma cells. Aging (Albany NY) 11, 11040–11053. https://doi.org/10.18632/aging.102508 (2019).

27. Pinato, D. J., North, B. V. & Sharma, R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: The prognostic nutritional index (PNI). Br. J. Cancer 106, 1439–1445. https://doi.org/10.1038/bjc.2012.92 (2012).

28. Cross, T. J. et al. King’s Score: An accurate marker of cirrhosis in chronic hepatitis C. Eur. J. Gastroenterol. Hepatol. 21, 730–738. https://doi.org/10.1097/MEG.0b013e32830fcf3 (2009).

29. Islam, S., Antonsson, L., Westin, J. & Lagging, M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand. J. Gastroenterol. 40, 867–872. https://doi.org/10.1080/003655205010015674 (2005).

30. Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (Baltimore, Md.) 43, 1317–1325. https://doi.org/10.1002/hep.21178 (2006).

31. Feng, J. et al. Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int. 28, 1408–1416. https://doi.org/10.1111/j.1478-3231.2008.01784.x (2008).

32. Zhou, K. et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 25, 1569–1577. https://doi.org/10.1111/j.1440-1746.2010.06383.x (2010).

33. Cross, T. J. et al. King’s Score: An accurate marker of cirrhosis in chronic hepatitis C. Eur. J. Gastroenterol. Hepatol. 21, 730–738. https://doi.org/10.1097/MEG.0b013e32830fcf3 (2009).

34. Islam, S., Antonsson, L., Westin, J. & Lagging, M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand. J. Gastroenterol. 40, 867–872. https://doi.org/10.1080/003655205010015674 (2005).

35. Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (Baltimore, Md.) 43, 1317–1325. https://doi.org/10.1002/hep.21178 (2006).

36. Feng, J. et al. Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int. 28, 1408–1416. https://doi.org/10.1111/j.1478-3231.2008.01784.x (2008).

37. Zhou, K. et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 25, 1569–1577. https://doi.org/10.1111/j.1440-1746.2010.06383.x (2010).
52. Lemoine, M. et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. *Gut* [https://doi.org/10.1136/gutjnl-2015-309260](https://doi.org/10.1136/gutjnl-2015-309260) (2015).

**Author contributions**
All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Correspondence and requests for materials should be addressed to Z.-G.S. or H.C.

Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2021